Executive Brief

News Report

The News: FDA approves over-the-counter adapalene and benzoyl peroxide for acne treatment.
Clinical Win: This approval enhances access to effective acne management for patients.
Target Specialty: Dermatology

Key Data at a Glance

FDA Approval Date: April 2026
Product Names: Differin, Epiduo
Indication: Mild to moderate acne

The FDA has approved the over-the-counter sale of adapalene and benzoyl peroxide combination products, including Differin and Epiduo, for the treatment of mild to moderate acne. This decision, announced in April 2026, is significant for healthcare providers as it expands treatment options for patients seeking effective acne management without a prescription.

Clinical Context

Acne is one of the most common dermatological conditions, affecting millions of adolescents and adults worldwide. It is characterized by the presence of comedones, papules, pustules, and sometimes cysts, primarily due to hormonal changes, increased sebum production, and bacterial colonization. Current treatment options include topical retinoids, benzoyl peroxide, and antibiotics, which are often prescribed in combination for enhanced efficacy. However, access to prescription medications can be a barrier for many patients, particularly those with mild to moderate acne. The recent FDA approval of over-the-counter adapalene and benzoyl peroxide products aims to bridge this gap, providing patients with effective treatment options readily available at pharmacies. This change is particularly relevant as it aligns with evolving treatment guidelines that emphasize the importance of early intervention in acne management to prevent scarring and psychological distress associated with the condition.

Key Findings

The FDA approval allows for the over-the-counter sale of adapalene and benzoyl peroxide combination products, including Differin and Epiduo, for the treatment of mild to moderate acne [1].
Clinical studies have demonstrated that the combination of adapalene and benzoyl peroxide significantly reduces acne lesions compared to placebo [2].
The recommended dosing for these products is typically once daily, applied to affected areas after cleansing [3].
Clinicians should consult current prescribing information for full dosing guidance.
The approval is expected to improve patient access to effective acne treatment, particularly for those who may not seek prescription options due to cost or accessibility issues [4].

What This Means for Clinical Practice

The approval of over-the-counter adapalene and benzoyl peroxide products provides clinicians with a new tool to recommend to patients with mild to moderate acne. This change allows for more immediate treatment options, enabling patients to manage their condition without the need for a prescription. Clinicians should consider discussing these options during consultations, particularly for patients who may be hesitant to seek prescription treatments due to cost or accessibility concerns. Additionally, the availability of these products may encourage early intervention, potentially reducing the severity of acne and its associated psychosocial impacts. As these products become more widely available, it will be essential for clinicians to stay informed about their use and efficacy to guide patients effectively.

Clinical Perspective

Workflow: Clinicians can now recommend over-the-counter options for patients with mild to moderate acne, streamlining treatment access.

Economics: This approval may reduce healthcare costs by decreasing the need for prescription visits for acne management.

Patient Outcomes: Improved access to effective treatments can lead to better patient adherence and outcomes in managing acne.

Dr. Divya Agarwal, Dermatology

FDA Approves Over-the-Counter Adapalene and Benzoyl Peroxide for Mild to Moderate Acne Treatment

Executive Brief

Key Data at a Glance

Clinical Context

Key Findings

What This Means for Clinical Practice

Clinical Perspective

References

Get weekly drug updates for Dermatology in your inbox.

Related Drug Updates

FDA Approves Adapalene and Benzoyl Peroxide for OTC Acne Treatment: New Nonprescription Gel

FDA Approves Icotrokinra for Moderate-to-Severe Plaque Psoriasis: Oral IL-23 Antagonist Launches New Treatment Option

FDA Approves Bimekizumab for Moderate to Severe Plaque Psoriasis: 75% Skin Clearance in BE VIVID Trial

Verified HCP Portal